• Liproxstatin-1 HCl: Precision Ferroptosis Inhibition in Mode

  2026-04-28

  Liproxstatin-1 HCl empowers researchers to dissect ferroptosis with nanomolar precision, offering robust protection against lipid peroxidation in acute renal and hepatic injury models. This guide details actionable workflows, troubleshooting strategies, and key innovations anchored in the latest mitochondrial calcium signaling research.

• GI 254023X: Mechanistic Insights into ADAM10 Inhibition and

  2026-04-28

  Explore the unique mechanistic profile of GI 254023X as an ADAM10 inhibitor, with a focus on molecular selectivity, signaling modulation, and best practices for translational assay design. This article provides advanced, evidence-based perspectives for researchers seeking to optimize experimental outcomes.

• Mitochondrial Calcium Signaling Represses Ferroptosis via GP

  2026-04-27

  This study uncovers a direct mechanistic link between mitochondrial calcium signaling through the MCU channel and the suppression of ferroptotic cell death. By demonstrating that mitochondrial calcium modulates GPX4 acetylation and activity, the research provides new avenues for targeting ferroptosis in disease models such as cancer, acute renal failure, and hepatic ischemia/reperfusion injury.

• SERCA2 Dysfunction, Inflammation, and Oxidative Stress in Pu

  2026-04-27

  This study uncovers a mechanistic link between SERCA2 dysfunction and pulmonary vascular remodeling through inflammation and oxidative stress. By implicating the PPARγ/PGC1α/Nrf2 pathway, the findings suggest new molecular targets for research into pulmonary hypertension and related vascular diseases.

• Verapamil HCl Targets Txnip: Novel Osteoporosis Mechanisms

  2026-04-26

  This study demonstrates that Verapamil HCl, an L-type calcium channel blocker, can attenuate osteoporosis in mice by inhibiting Txnip and modulating bone turnover pathways. The findings highlight new molecular targets and mechanisms in bone remodeling, with implications for translational osteoporosis research.

• Sunitinib: Multi-Targeted RTK Inhibitor in RCC Research

  2026-04-25

  Sunitinib’s low-nanomolar potency and versatility as a multi-targeted receptor tyrosine kinase inhibitor make it essential for dissecting angiogenesis, cell proliferation, and drug resistance in renal cell carcinoma and other tumor models. Recent advances, such as metabolic co-targeting strategies, offer researchers fresh avenues to overcome resistance and maximize experimental impact.

• BMN 673 (Talazoparib): Precision in DNA Repair Deficiency Ta

  2026-04-24

  BMN 673 (Talazoparib) sets a new benchmark in homologous recombination deficient cancer research by delivering ultra-potent and selective PARP1/2 inhibition. This guide details practical workflows, experimental enhancements, and troubleshooting strategies to maximize data quality, leveraging recent mechanistic breakthroughs for translational success.

• I-BET151 (GSK1210151A) Practical Guide for BET Bromodomain I

  2026-04-24

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor designed for research workflows examining gene regulation, cancer biology, and apoptosis. It is best suited for cell-based and in vivo studies where precise modulation of BRD2/BRD3/BRD4 activity is required. Use is restricted to scientific research, not diagnostic or therapeutic applications.

• Phosbind Acrylamide: Decoding Phosphorylation for Translatio

  2026-04-23

  This thought-leadership article explores how Phos binding reagent (Phosbind) acrylamide revolutionizes protein phosphorylation analysis, drawing on mechanistic insight, recent plant kinase research, and strategic guidance for translational investigators. It contextualizes the reagent’s value in antibody-free phosphorylation detection, bridges novel findings from the SmCPK24 kinase-WRKY1 axis in Salvia miltiorrhiza, and delivers actionable recommendations for experimental design.

• Caffeic Acid Phenethyl Ester Inhibits C. difficile Toxins an

  2026-04-23

  Guo et al. (2025) demonstrate that caffeic acid phenethyl ester (CAPE) directly inhibits the major toxin TcdB of Clostridioides difficile and favorably alters gut microbiota in a murine infection model. This dual action highlights CAPE's promise as a lead compound for antivirulence therapy in antibiotic-resistant CDI.

• MEK1/2-c-Myc:MAX Axis Prevents Polycomb Repression of TERT i

  2026-04-22

  This study reveals a cooperative mechanism between MEK1/2 kinases and the c-Myc:MAX complex that safeguards TERT transcription in human pluripotent stem cells by preventing PRC2-mediated chromatin repression. The findings clarify how MEK-ERK pathway activity maintains telomerase expression, with implications for stem cell biology and targeted pathway inhibition research.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Workflo

  2026-04-22

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, empowers researchers to dissect the ubiquitin-proteasome system and modulate NF-κB signaling with high specificity. This guide translates primary literature and advanced protocols into actionable workflows, bridging inflammation, apoptosis, and tumor immunity research.

• Translating TGF-β Dual Inhibition: Strategy and Mechanism wi

  2026-04-21

  A thought-leadership article for translational researchers, dissecting the mechanistic and strategic advantages of dual TGF-β receptor inhibition using LY2109761. This piece integrates recent advances in the molecular understanding of TGF-β-mediated cytostasis, the role of Smad2/3 phosphorylation, and the translational relevance of targeting the TGF-β pathway in cancer and fibrosis models. With protocol guidance, evidence-backed insights, and a vision for future research, this article positions LY2109761 (TβRI/II kinase inhibitor) from APExBIO as a pivotal tool for advancing preclinical and translational studies.

• HOBt (1-Hydroxybenzotriazole): Expanding Peptide Synthesis H

  2026-04-21

  Discover how HOBt (1-Hydroxybenzotriazole) enables advanced peptide synthesis and amide bond formation while minimizing epimerization. This article explores mechanistic insights, protocol optimization, and the future of racemization control, offering unique scientific depth beyond standard workflows.

• M344: Histone Deacetylase Inhibitor for Advanced Cancer Rese

  2026-04-20

  M344 stands apart as a potent, cell-permeable histone deacetylase inhibitor, enabling precise epigenetic modulation in diverse cancer models and HIV-1 latency workflows. This article guides researchers through practical applied protocols, troubleshooting, and comparative advantages, leveraging robust evidence and APExBIO’s trusted supply chain.

16443 records 1/1097 page Next 12345 下5页 Last page